Clusterin Protects Hepatocellular Carcinoma Cells from Endoplasmic Reticulum Stress Induced Apoptosis through GRP78

Clusterin Interacts with Paclitaxel and Confer Paclitaxel Resistance in Ovarian Cancer

(2015) Dong Choon Park et al.   NEOPLASIA

Survivin-mediated Therapeutic Efficacy of Gemcitabine through Glucose-regulated Protein 78 in Hepatocellular Carcinoma

(2012) Chin-Sheng Hung et al.   ANNALS OF SURGICAL ONCOLOGY

Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model

(2012) Cun Wang et al.   BMC CANCER

Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model

(2012) Y Kususda et al.   BRITISH JOURNAL OF CANCER

Small heat shock proteins in cancer therapy and prognosis

(2012) Amina Zoubeidi et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Tumor-derived secretory clusterin induces epithelial–mesenchymal transition and facilitates hepatocellular carcinoma metastasis

(2012) Cun Wang et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Expressions of GRP78 and Bax associate with differentiation, metastasis, and apoptosis in non-small cell lung cancer

(2012) Qing Sun et al.   MOLECULAR BIOLOGY REPORTS

Glucose-Regulated Protein 78 (GRP78) Mediated the Efficacy to Curcumin Treatment on Hepatocellular Carcinoma

(2011) Yu-Jia Chang et al.   ANNALS OF SURGICAL ONCOLOGY

Clusterin Inhibition Using OGX-011 Synergistically Enhances Hsp90 Inhibitor Activity by Suppressing the Heat Shock Response in Castrate-Resistant Prostate Cancer

(2011) F. Lamoureux et al.   CANCER RESEARCH

Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c

(2011) F. Saad et al.   CLINICAL CANCER RESEARCH

Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer

(2011) Janessa J. Laskin et al.   Journal of Thoracic Oncology

Grp78 promotes the invasion of hepatocellular carcinoma

(2010) Rongjian Su et al.   BMC CANCER

Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer

(2010) A. Zoubeidi et al.   CLINICAL CANCER RESEARCH

Endoplasmic reticulum stress in liver disease

(2010) Harmeet Malhi et al.   JOURNAL OF HEPATOLOGY

Clusterin Facilitates COMMD1 and I- B Degradation to Enhance NF- B Activity in Prostate Cancer Cells

(2010) A. Zoubeidi et al.   MOLECULAR CANCER RESEARCH

Glucose-Regulated Protein 78 Is a Novel Contributor to Acquisition of Resistance to Sorafenib in Hepatocellular Carcinoma

(2009) Jeng-Fong Chiou et al.   ANNALS OF SURGICAL ONCOLOGY

Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors

(2009) Tao Liu et al.   EUROPEAN JOURNAL OF CANCER

Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer

(2009) Li Wei et al.   INTERNATIONAL JOURNAL OF CANCER

Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation

(2009) Kuen-Feng Chen et al.   JOURNAL OF HEPATOLOGY

Clusterin Activates Survival through the Phosphatidylinositol 3-Kinase/Akt Pathway

(2008) Hayet Ammar et al.   JOURNAL OF BIOLOGICAL CHEMISTRY